{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"groups":[{"description":"Participants were administered belantamab mafodotin with recommended phase 2 dose (RP2D) of 2.5 mg/kg in combination with 200 mg of pembrolizumab via IV infusion on Day 1 of each 21-day Cycle up to until disease progression, intolerable toxicity, informed consent withdrawal, or for a maximum of 35 cycles.","id":"OG000","title":"Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion"}],"populationDescription":"All Treated Population. Data was not collected","reportingStatus":"POSTED","timeFrame":"Baseline (Day 1) and up to approximately 178 weeks","title":"Part 2 - Number of Participants With Post-baseline Decline in BCVA to Light Perception or no Light Perception","type":"SECONDARY"}